shares of celgene advanced about 1%. biogen i-dec also getting a small boost today on the back of positive results from two late- stage studies that its multiple sclerosis pill significantly reduces relapses and the progression of disability related to m.s. shares of biogen were up a dime to $147 a share. and, one initial public offering started trading here at the new york stock exchange. shares of work-day soared 74% as the market for business to business software continues to hold strong. shares in j.b. hunt transportation were on a roll. several analysts, impressed with growth in some key operations raised their price target. j.b. hunt was the best performer in the dow transports today, rising 6.5%. as we mentioned earlier, there was weakness in financials. this pulled down the s.p.d.r. financials e.t.f. it was the hardest hit among our most actively traded e.t.f.s. and that's tonight's market focus. >> susie: the major stock averages are down about one percent for october, but our market monitor is bullish. james pa

i think i want to own celgene and buy celgene right here. let's go to janet in ohio. >> caller: yes, we love you here in ohio. >> thank you. >> caller: i'm calling about devon energy which i bought a while ago and i have been losing a pot load of money. >> me too. talk about david -- they said they were moving more toward oil. they have not been able to do so. it's a distinct disappointment. i'm not couching that. devon is a disappointment. let's go to mary in california. mary? >> caller: boo-ya, cramer. >> go ahead. >> caller: can you give me the long and short of sears holdings? >> until you tell me you want to shop at sears, i don't recommend it. eddie lampard, he runs the company, but you know what? no. i won't shop there. i don't want to own the stock. i shop pretty much everywhere. jeff in minnesota, please. >> caller: from the land of the most undervalued football team in the nfl. >> i like the vikings, i had ponder. he was back to the old fsu self. what's the stock? >> caller: what do you think of the steel company archer? >> sell th

go celgene. let's go to ed in new york, please. ed? >> caller: hey. >> hey. modern portfolio.opeye's. i love the red beans and rice. aig is my favorite financial. michael kors is the terrific apparel company where they still charge $200 even at the outlets. dynavax. and facebook is not doing as badly as everybody else. internet company, financial, apparel company, biotech and we've got a restaurant, i say, bingo! deloris in new york. deloris? >> caller: hi, jim. boo-yah to you. >> i'll be there this weekend. clinton hill is coming back. go ahead. >> caller: we love you, jim. you do so much for us. >> thank you. >> caller: i want to know if i'm diversified. my first stock is target, second is sirius xm, third is clorox, fourth is disney and last is johnson & johnson. >> all right. let me go to work. the classic final station, 26 can't be beaten. sirius is entertainment. disney -- let's call it radio. that would conflict with disney. that's true entertainment. johnson & johnson, pharma. target one of the best retailers in the world. and clorox -- too much like johnson & johnson.

i like celgene and gilead because they have great drugs in the pipeline.na is offered it to be a takeover target. i can't recommend stocks on the basis of that. i say take off half. don in colorado. >> jim, a big larod though rocky mountain high boo-yah to you. >> let me give you a peyton manning destroyed me on fantasy boo-yah. what's up? >> me, too. my stock -- >> a specialty chemical company. i can give you dupont, which has a good yield, good management and is less expensive. james in wisconsin. >> hey jim. >> hey james. >> boo-yah. >> boo-yah. >> what is the best time to invest in wwe, before or after wrestlemania? >> how about no time? one of those things, you give me that the either/or, i've got to give you the know because i don't think this stock is worth owning. it's got no growth. a yield but no growth is not enough for me to be tim in georgia. >> a big downtown boo-yah to you. i was calling to ask you about facebook. they're going up or down? >> look, there is going to be a couple lockups that expire where there is going to be hundreds of milli

celgene selling its cancer drug.tly investigating the role in treating other forms, including pancreatic and melanoma. that's a common trend we continue to see in the biotech space, finding multiple uses of one drug, making it much more versatile and profitable. back to you. >> and the stock is up a percent. tough to find anything that's up that much today. thank you very much. tight trade for stocks as we head into the close here this friday. a lot could drive the markets next week. we want to look ahead. among the companies reporting earnings, key financials. goldman sachs, bank of america, intel, and microsoft. both those sectors have been the major pillars for the equity market this year. how might these numbers affect sentiment next week? >> gentlemen, nice to have you both here on the set. david, your assessment of what earnings season is going to look like next week, considering this week we've had declines every day. >> michelle, bob, bill, the negative preannouncements are leading the positive preannouncemen

. >> we're offering shares of celgene after the earlier release of a european medicine's agency report on their cancer drug. ema is expressing concern about the risk/benefit of the drug and that's sending the stock lower today. in a pre-open note from citi, analysts noted that the document is disappointing but he does believe that it is biased in its scientific analyst. we'll have to continue to watch for follow-up on this but sending the stock down by 4.5% today. >>> we're keeping an eye on microsoft. the ceo there, steve balmer, telling shareholders he wants to be more of a device and services outfit to be more like apple. in a letter to shareholders, ballmer also suggested the company may one day make its own phone to build on its upcoming tablet pc. microsoft cut ballmer's bonus because of slow progress at its online new kniunit. he's now getting $620,000. the max was $3.7 million. ballmer remains bullet-proof. let's talk more with with the deputy managing editor at "wall street journal," and and our jon fortt. welcome to you both. start with the pivot of the company, spencer, to o

this is the celgene of ag.eople are getting negative on this. >> you talked mosaic last night as well. >> the ceo was on and i liked it but he was not saying pound on the table. they have a very interesting move in may that they can do to start buying back stock. they are locked in right now. but monsanto on the dip i think is buyable. >> you talked costco last night. there have been some analysts that have missed a run. you think in the end they might be right at this point? >> i've got to hold back here. here's the problem. we know there's a negative analyst out there. we know if these guys don't exceed the numbers -- by the way, you remember costco tvs. they don't like to raise price. on your great documentary you talked about that. >> b of a is positive. >> i'm just scared. i think it's such a big run if they miss out versus family dollar which didn't really do that great but expectations are so low it's going up. >> serial disappointor. >> when we come back, kyle bass is going to give us his assessment of

. >> looking at shares of celgene.r treatment abraxane. it treats the most common form of lung cancer and this could bring in an additional $110 million worth of sales to cellgene's, up 2.4%. >> to the cme group, rick santelli who already had a fantastic interview with robert sh schiller this morning. >> what an absolute guy he is and i thank the cme for letting that happen. yesterday steve liesman with his interview, with of course mr. erskine, mr. bowles and lloyd blankfein was an a plus, plus, plus, plus, plus and i particularly enjoyed some of the dialogue between mr. blankfein and steve regarding the fiscal cliff. debris there is an upside to the fiscal cliff but i think traders on this floor, they look at the fiscal cliff in a much different way. i'll tell you what i mean by that. we have fiscal cliff but what traders say is, that the real issue is the philosophical cliff, and i'll tell you what i mean by that. the fiscal cliff issues, you look at the markets, they seem nonplussed, okay? if build blankfein's righ